366 related articles for article (PubMed ID: 36397950)
1. Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease.
Yang B; Yang X; Tan X; Lu L; Fan W; Barbier-Torres L; Steggerda J; Liu T; Yang H
Can J Gastroenterol Hepatol; 2022; 2022():6799414. PubMed ID: 36397950
[TBL] [Abstract][Full Text] [Related]
2. Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.
Yang B; Lu L; Zhou D; Fan W; Barbier-Torres L; Steggerda J; Yang H; Yang X
Front Endocrinol (Lausanne); 2022; 13():1007944. PubMed ID: 36267567
[TBL] [Abstract][Full Text] [Related]
3. NF-κB-upregulated miR-155-5p promotes hepatocyte mitochondrial dysfunction to accelerate the development of nonalcoholic fatty liver disease through downregulation of STC1.
Shen M; Pan H; Ke J; Zhao F
J Biochem Mol Toxicol; 2022 Jun; 36(6):e23025. PubMed ID: 35603999
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines.
Panera N; Della Corte C; Crudele A; Stronati L; Nobili V; Alisi A
Expert Rev Gastroenterol Hepatol; 2016; 10(3):393-403. PubMed ID: 26654761
[TBL] [Abstract][Full Text] [Related]
5. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
[TBL] [Abstract][Full Text] [Related]
7. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
[TBL] [Abstract][Full Text] [Related]
8. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Ezhilarasan D; Lakshmi T
Oxid Med Cell Longev; 2022; 2022():9233650. PubMed ID: 35602098
[TBL] [Abstract][Full Text] [Related]
9. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway.
Chen M; Xing J; Pan D; Peng X; Gao P
Biomed Pharmacother; 2020 Aug; 128():110286. PubMed ID: 32521450
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
12. Hepatokines and non-alcoholic fatty liver disease.
Lebensztejn DM; Flisiak-Jackiewicz M; Białokoz-Kalinowska I; Bobrus-Chociej A; Kowalska I
Acta Biochim Pol; 2016; 63(3):459-67. PubMed ID: 27262842
[TBL] [Abstract][Full Text] [Related]
13. Macrophages as Key Players during Adipose Tissue-Liver Crosstalk in Nonalcoholic Fatty Liver Disease.
Korf H; Boesch M; Meelberghs L; van der Merwe S
Semin Liver Dis; 2019 Jul; 39(3):291-300. PubMed ID: 31041786
[TBL] [Abstract][Full Text] [Related]
14. Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future.
Santos JPMD; Maio MC; Lemes MA; Laurindo LF; Haber JFDS; Bechara MD; Prado PSD; Rauen EC; Costa F; Pereira BCA; Flato UAP; Goulart RA; Chagas EFB; Barbalho SM
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008925
[TBL] [Abstract][Full Text] [Related]
15. Sini powder ameliorates the inflammatory response in rats with stress-induced non-alcoholic fatty liver disease by inhibiting the nuclear factor kappa-B / pyrin domain-containing protein 3 pathway.
Mu J; Cheng F; Wang Q; Wang X; Zhu W; Ma C; Yin X; Ren B; Lian Y; Du X; Zhang H; Liu S; Zhang S
J Tradit Chin Med; 2020 Apr; 40(2):253-266. PubMed ID: 32242391
[TBL] [Abstract][Full Text] [Related]
16. Macrophage SCAP Contributes to Metaflammation and Lean NAFLD by Activating STING-NF-κB Signaling Pathway.
Huang X; Yao Y; Hou X; Wei L; Rao Y; Su Y; Zheng G; Ruan XZ; Li D; Chen Y
Cell Mol Gastroenterol Hepatol; 2022; 14(1):1-26. PubMed ID: 35367665
[TBL] [Abstract][Full Text] [Related]
17. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis.
Atanasovska B; Rensen SS; Marsman G; Shiri-Sverdlov R; Withoff S; Kuipers F; Wijmenga C; van de Sluis B; Fu J
Cells; 2021 Jul; 10(8):. PubMed ID: 34440652
[TBL] [Abstract][Full Text] [Related]
19. C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD.
Yan FJ; Wang X; Wang SE; Hong HT; Lu J; Ye Q; Zheng YL; Wang YJ
Biochem J; 2020 Feb; 477(3):691-708. PubMed ID: 31957809
[TBL] [Abstract][Full Text] [Related]
20. The role of AMPKα2 in the HFD-induced nonalcoholic steatohepatitis.
Zhang X; Liu S; Zhang C; Zhang S; Yue Y; Zhang Y; Chen L; Yao Z; Niu W
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165854. PubMed ID: 32502647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
